A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine

Completed · Phase 4

Conditions studied: Post Operative Pain

In brief

This prospective, single-arm feasibility study will evaluate postoperative pain control, opioid use, and early recovery outcomes in adult patients undergoing elective outpatient facial plastic surgery who receive suzetrigine as part of their standard postoperative analgesic regimen.

Key facts

Study ID

NCT07257133

Run by

Mayo Clinic

People needed

100

Starts

2025-10-20

Expected to finish

2026-04-01

Last updated by the study team

2026-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥18 years) undergoing elective outpatient facial plastic surgery.
• Able to consent and comply with study procedures.
• Planned postoperative use of suzetrigine per provider discretion.

You may not qualify if…

• Age <18.
• Pregnant or breastfeeding.
• Women on hormonal birth control who decline suzetrigine-related counseling.
• Patients using strong CYP3A4 inhibitor medications (i.e. itraconazole, ketoconazole, clarithromycin, ritonavir, and grapefruit juice).
• Known allergy to suzetrigine.
• Vulnerable or protected research populations.

Where it is running

• Mayo Clinic in Florida — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.